Clinical Care Team | VELPHORO® (sucroferric oxyhydroxide)

Peer-to-peer videos

Hear how your peers talk to their patients about the unique features of Velphoro, and find out how Velphoro can help with some of the challenges of phosphate management.

The need for potent phosphate binding*

Renal dietitians share their views on why helping patients achieve their phosphorus goals can be challenging, and how Velphoro, the most potent phosphate binder, may help.1

The need for potent phosphate binding*

Renal dietitians share their views 3 on why helping patients achieve their phosphorus goals can be challenging, and how Velphoro, the most potent phosphate binder, may help.2

Educating patients on how to take Velphoro*

Hear renal dietitians talk about why they like the flexibility of Velphoro administration,2 and how they educate their patients about the different ways to take it.

Putting patients in control with Velphoro*

Dialysis and hyperphosphatemia may make some patients feel out of control. Renal dietitians talk, peer-to-peer, about their confidence in Velphoro, and how putting patients in control of how to take it can help.

Setting expectations with Velphoro*

Guidance from renal dietitians focuses on giving patients a better chance of success by setting expectations for Velphoro treatment.

Clinical Care Team Guide

Lighten Their Journey, a Clinical Care Team Guide to Supporting Patients on Velphoro

The Clinical Care Team Guide is a comprehensive resource to help support patients. The guide and patient handouts are available from your Velphoro representative. Request a visit today. 

Additional copies of the patient handouts are available (in English and Spanish) and can be downloaded below.

American Kidney Fund phosphorus overview
Phosphorus Overview

Helps patients understand phosphorus and the importance of controlling phosphorus levels.

Get the handout
Get the handout in Spanish
Are you taking too many pills? patient handout
Are You Taking Too Many Pills?

Explains how a more potent phosphate binder can help, and what questions patients should ask you about Velphoro treatment. 

Get the handout
Get the handout in Spanish
Velphoro Fact Sheet
Velphoro Fact Sheet

Provides important dosing and administration information for patients when they’re starting Velphoro.

Get the Handout
Get the handout in Spanish
Commonly asked questions about Velphoro
Patient Q&A

Answers commonly asked questions about Velphoro, and links to videos on the patient website.

Get the Handout
Get the handout in Spanish
Staying on track with Velphoro
Staying on Track

Supports patients with tips on remembering to take Velphoro so they can stay on track with treatment.

Get the Handout
Get the handout in Spanish
Long-term Therapy with Velphoro
Long-Term Therapy

Provides a primer on phosphorus goals, understanding the phosphorus lab report, and tracking phosphorus levels over time.

Get the Handout
Get the handout in Spanish
Seasonal certificates to recognize a patient's progress
Patient Certificates (seasonal themes)

Recognize a patient's progress toward their phosphorus goals throughout the year.

Get the certificates
Get the certificates in Spanish
A certificate to recognize a patient's progress
Patient Certificate

Acknowledges a patient’s progress toward their phosphorus goal. 

Get the certificate
Get the certificate in Spanish

*Presenter is a paid speaker and has been compensated for their time. 

References: 1. Coyne DW, Larson DS, Delmez JA. Bone disease. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed, Philadelphia, PA: Wolters Kluwer Health; 2015:665-692. 2. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2020.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451